Go Pro
→ The world’s least risky AI stock? (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$74.71
-3.0%		$68.72
$24.85
▼
$79.39
$6.82B0.23852,228 shs748,814 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$53.06
-1.4%		$50.64
$27.07
▼
$58.49
$6.55B0.691.06 million shs942,942 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$64.23
-1.6%		$61.13
$35.60
▼
$72.66
$6.31B0.62694,226 shs496,371 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$25.76
+3.3%		$24.01
$13.48
▼
$29.75
$1.77B1.15450,557 shs664,292 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-2.96%-0.19%+4.10%+11.62%+182.03%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-1.41%+0.80%-1.34%+7.52%+65.92%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-1.58%-0.50%-4.56%+18.09%+70.51%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+3.33%+11.37%+4.46%+7.65%+84.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$74.71
-3.0%		$68.72
$24.85
▼
$79.39
$6.82B0.23852,228 shs748,814 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$53.06
-1.4%		$50.64
$27.07
▼
$58.49
$6.55B0.691.06 million shs942,942 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$64.23
-1.6%		$61.13
$35.60
▼
$72.66
$6.31B0.62694,226 shs496,371 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$25.76
+3.3%		$24.01
$13.48
▼
$29.75
$1.77B1.15450,557 shs664,292 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-2.96%-0.19%+4.10%+11.62%+182.03%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-1.41%+0.80%-1.34%+7.52%+65.92%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-1.58%-0.50%-4.56%+18.09%+70.51%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+3.33%+11.37%+4.46%+7.65%+84.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$83.1811.34% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.12
Buy$57.718.77% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$77.1320.09% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.82
Moderate Buy$40.7558.19% Upside

Current Analyst Ratings Breakdown

Latest ZYME, CGON, SRRK, and XENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$56.00 ➝ $63.00
8/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00 ➝ $44.00
8/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$65.00
8/10/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$74.00
8/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$58.00
8/7/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$46.00
8/7/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$82.00 ➝ $81.00
8/7/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$76.00
8/7/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$37.00 ➝ $40.00
8/7/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$58.00 ➝ $60.00
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,639.18N/AN/A$9.33 per share8.01
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$2.41 per shareN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M827.88N/AN/A$12.85 per share5.00
Zymeworks Inc. stock logo
ZYME
Zymeworks
$105.96M17.25N/AN/A$1.13 per share22.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-26.58%-25.34%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.45N/AN/AN/AN/A-159.92%-90.71%N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%11/2/2026 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$81.13M-$2.02N/A644.00N/A-405.31%-72.30%-37.18%N/A

Latest ZYME, CGON, SRRK, and XENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.5620-$0.62-$0.0580-$0.62$4.54 million$3.23 million
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/6/2026Q2 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8405-$0.84+$0.0005-$0.84$3.33 millionN/A
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
31.30
31.25
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.71
8.64
8.64
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
6.32
6.32

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
Zymeworks Inc. stock logo
ZYME
Zymeworks
33.51%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.64 million84.39 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
140121.79 million109.24 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21096.67 million93.85 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46070.96 million47.18 millionN/A

Recent News About These Companies

FY2026 EPS Estimates for Zymeworks Cut by HC Wainwright
August 13 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30957526
Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright
August 12 at 6:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-earnings-estimate-for-zymeworks-issued-by-hc-wainwright-2026-08-12/
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
August 11 at 10:31 AM  |  zacks.comhttps://www.zacks.com/stock/news/2972612/tbph-meets-q2-earnings-estimates-to-be-acquired-by-zymeworks?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2972612
HC Wainwright Issues Negative Outlook for Zymeworks Earnings
August 11 at 7:57 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-negative-outlook-for-zymeworks-earnings-2026-08-11/
Zymeworks Steps Up Investor Outreach with September Conference Lineup
August 11 at 6:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zymeworks-steps-up-investor-outreach-with-september-conference-lineup?utm_source=marketbeat.com&utm_medium=referral
Zymeworks Announces Participation in Upcoming Investor Conferences
August 11 at 6:11 AM  |  financialpost.comF
Zymeworks Inc. to Participate in Upcoming Investor Conferences in September
August 11 at 6:11 AM  |  quiverquant.comQ
Zymeworks (NASDAQ:ZYME) Update Puts Antibody Strategy In Focus
August 9, 2026  |  kalkinemedia.comK
Truist Financial Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) Stock
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30950952
Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-has-3273-million-stake-in-zymeworks-inc-zyme-2026-08-09/
Wells Fargo Remains a Buy on Zymeworks (ZYME)
August 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZYME/pressreleases/3665084/wells-fargo-remains-a-buy-on-zymeworks-zyme/
HC Wainwright Has Negative Outlook for Zymeworks Q3 Earnings
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947744
Zymeworks (NASDAQ:ZYME) Issues Earnings Results, Misses Expectations By $0.05 EPS
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zymeworks-nasdaqzyme-issues-earnings-results-misses-expectations-by-005-eps-2026-08-07/
Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, Truist Financial Analyst Says
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zymeworks-nasdaqzyme-stock-price-expected-to-rise-truist-financial-analyst-says-2026-08-07/
What is HC Wainwright's Forecast for Zymeworks Q2 Earnings?
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-forecast-for-zymeworks-q2-earnings-2026-08-07/
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970526/zymeworks-inc-zyme-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2970526
What is HC Wainwright's Estimate for Zymeworks Q3 Earnings?
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-estimate-for-zymeworks-q3-earnings-2026-08-06/
Segall Bryant & Hamill LLC Takes Position in Zymeworks Inc. $ZYME
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-segall-bryant-hamill-llc-takes-position-in-zymeworks-inc-zyme-2026-08-06/
Zymeworks Inc. (NASDAQ:ZYME) Receives $37.33 Average Price Target from Brokerages
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30944588
A Post Acquisition Look At Zymeworks
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930635-a-post-acquisition-look-at-zymeworks
Perceptive Advisors LLC Increases Stock Holdings in Zymeworks Inc. $ZYME
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-perceptive-advisors-llc-increases-stock-holdings-in-zymeworks-inc-zyme-2026-08-02/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$74.71 -2.28 (-2.96%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$75.14 +0.44 (+0.58%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$53.06 -0.76 (-1.41%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$53.05 -0.01 (-0.02%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$64.23 -1.03 (-1.58%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$64.52 +0.29 (+0.45%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Zymeworks stock logo

Zymeworks NASDAQ:ZYME

$25.76 +0.83 (+3.33%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$26.00 +0.24 (+0.93%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas